Penetration of cefuroxime into chronically inflamed sinus mucosa

Laryngoscope

Volumn 109, Issue 11, 1999, Pages 1841-1847

  Dínìs, Paulo Borges ^a   Monteiro, Maria Conceição ^a   Lobato, Rosário ^b   Martins, Maria Luz ^a   Gomes, Augusto ^a  

^a HOSPITAL PULIDO VALENTE   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Cefuroxime axetil; Chronic sinusitis; Sinonasal mucosa; Tissue penetration

Indexed keywords

CEFUROXIME AXETIL;

ADULT; AGED; ARTICLE; CHRONIC SINUSITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CEFUROXIME; CEPHALOSPORINS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NASAL MUCOSA; RHINITIS; SINUSITIS; TISSUE DISTRIBUTION;

EID: 0344183047     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199911000-00023     Document Type: Article

References (34)

1. Gwaltney JM, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992;90:457-462.
2. Schentag JJ, Swanson DJ, Smith IL. Dual individualization: antibiotic dosage calculation form the integration of invitro pharmacodynamics and in-vivo pharmacokinetics. J Antimicrob Chemother 1985;15(Suppl A):47-57.
3. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991;35:1947-1952.
4. Lundberg C, Malmburg AS. Concentration of penicillin V and tetracycline in maxillary sinus secretion after repeated doses. Scand J Infect Dis 1973;5:123-133.
5. Sorri M, Peltomaki E, Jokinen K. Bacampicillin in acute maxillary sinusitis: concentration in sinus secretion and clinical effect - a randomized, double-blind study of two dosage regimens. Scand J Infect Dis 1981;13:277-280.
6. Stenquist M, Olen L, Jannert M, Näslund L, Zeckel ML. Penetration of Loracarbef into the maxillary sinus: a pharmacokinetic assessment. Clin Ther 1996;18:273-284.
7. Paavolainen M, Kohonen A, Palva T, Renkonen OV. Penetration of erythromycin stearate into maxillary sinus mucosa. and secretion in chronic maxillary sinusitis. Acta Otolaryngol (Stockh) 1977;84:292-295.
8. Karma P, Pukander J, Penttilä M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis 1991;10:856-859.
9. Jeppesen F, Illum P. Concentration, of ampicillin in antral mucosa following administration of ampicillin sodium and pivampicillin. Acta Otolaryngol (Stockh) 1972;73:428-432.
10. Sundberg L, Edén T, Ernstson S. Penetration of doxycycline in respiratory mucosa. Acta Otolaryngol (Stockh) 1983;96: 501-508.
11. Sudderick RM, Lund VJ, Thomson JP, McCombe A, Mackay IS. An evaluation of the penetration of cefuroxime axetil into human paranasal sinus tissue. Rhinology 1992;30: 11-16.
12. Harding SM, Williams PEO, Ayrton J. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob Agents Chemother 1984;25:78-82.
13. Brodie DP, Knight S, Cunningham K. Comparative study of cefuroxime axetil and amoxycillin in the treatment of acute sinusitis in general practice. J Int Med Res 1989;17: 547-551.
14. Sydnor A, Gwaltney JM, Coechetto DM, Scheld M. Comparative evaluation of cefuroxime axetil and cefaclor for treatment of acute bacterial maxillary sinusitis. Arch Otolaryngol Head Neck Surg 1989;115:1430-1433.
15. Camacho AE, Coso R, Otte J, et al. Clinical comparison of cefuroxime axetil and amoxycillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992;93:271-276.
16. Lund VJ, Kennedy BW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol 1995;104(Suppl 167):17-21.
17. Ginsburg CM, McCracken GH, Petruska M, Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob Agents Chemother 1985;28:504-507.
18. van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, Peeters MF. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 1997;349:683-687.
19. Lindbæk M, Hjortdahl P, Johnsen UL-H. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ 1996;313:325-329.
20. Scadding GK, Lund VJ, Darby YC. The effect of long-term antibiotic therapy upon ciliary beat frequency in chronic rhinosinusitis. J Laryngol Otol 1995;109:24-26.
21. Ishida LK, Ikeda K, Tanno N, Takasaka T, Nishioka K, Tanno Y. Erythromycin inhibits adhesion of Pseudomonas aeruginosa and Branhamella, catarrhalis to human nasal epithelial cells. Am J Rhinol 1995;9:53-55.
22. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-2080.
23. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrab Agents Chemother 1996;40: 1208-1213.
24. Nicolau DP, Quintiliani R. Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach. PharmacoEconomics 1994;5(Suppl 2):34-39.
25. Jetland O, Thurmann-Nielsen E, Walstad RA. Comparison of the serum and tissue concentrations of cefuroxime from cefaroxime axetil and phenoxymethylpenicillin in patients undergoing tonsillectomy. Int J Clin Pharmacol Res 1991; 11:1-6.
26. Schentag JJ. Clinical significance of antibiotic tissue penetration. Clin Pharmacokinetics 1989;16(Suppl 1): 25-31.
27. Cherrier P, Tod M, Le Gros V, Petitjean O, Brion N, Chatelin A. Cefotiam concentrations in the sinus fluid of patients with chronic sinusitis after administration of cefotiam hexetil. Eur J Clin Microbiol Infect Dis 1993;12:211-214.
28. Lang CC, Moreland TA, Davey PG. Bioavailability of cefuroxime axetil: comparison of standard and abbreviated methods. J Antimicrob Chemother 1990;25:645-650.
29. Wise R, Bennett SA, Dent J. The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid. J Antimicrob Chemother 1984;13:603-610.
30. Sommers DK, Van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol 1984;18:535-539.
31. James NC, Donn KH, Collins JJ, et al. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens. Antimicrob Agents Chemother 1991;35:1860-1863.
32. Sommers DK, Van Wyk M, Williams PEO, Harding SM. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984;25:344-347.
33. Ridgway E, Stewart K, Rai G, Kelsey MC, Bielawska C. The pharmacokinetics of cefuroxime axetil in the sick elderly patient. J Antimicrobial Chemother 1991;27:663-668.
34. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-840.